监测接种首剂后出现不良反应人群的 COVID-19 mRNA 疫苗第二剂。
Monitored COVID-19 mRNA vaccine second doses for people with adverse reactions after the first dose.
机构信息
From the Division of Infectious Diseases, University of Massachusetts Medical School-Baystate, Springfield, Massachusetts.
Employee Health Services, Baystate Health, Springfield, Massachusetts; and.
出版信息
Allergy Asthma Proc. 2022 Jan 1;43(1):37-39. doi: 10.2500/aap.2022.43.210100.
After Emergency Use Authorization of the coronavirus disease 2019 (COVID-19) vaccines, guidance was provided by the Centers for Disease Control and Prevention that persons with an immediate allergic reaction to a messenger RNA (mRNA) COVID-19 vaccine should be evaluated by an allergist/immunologist before receipt of the second dose. In vaccinating health-care personnel, we referred those with significant reactions to allergy/immunology specialists so that they could safely receive the second dose. We found that many reactions after the first dose were nonallergic but could be debilitating and a barrier to the second dose. We created a protocol of premedications to allow health-care personnel to safely receive their second mRNA COVID-19 vaccine dose. This protocol is adaptable and can be used in settings where allergy/immunology referral is not immediately available.
在获得针对 2019 年冠状病毒病（COVID-19）的紧急使用授权后，疾病控制与预防中心提供了指导意见，即对信使 RNA（mRNA）COVID-19 疫苗有即刻过敏反应的人应在接种第二剂疫苗之前由过敏症/免疫学专家进行评估。在为医护人员接种疫苗时，我们将那些对过敏/免疫学专家有严重反应的人转介过去，以便他们能够安全地接种第二剂疫苗。我们发现，第一剂后很多反应并不是过敏反应，但可能会使人衰弱，并且成为接种第二剂的障碍。我们制定了一个预先用药方案，使医护人员能够安全地接种第二剂 mRNA COVID-19 疫苗。该方案具有适应性，可以在没有过敏/免疫学专家的情况下使用。
Zotero 插件